FDA Approves Genentech's Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Core Insights - The U.S. FDA has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy [1] Company Summary - Genentech, a member of the Roche Group, is expanding its oncology portfolio with the recent FDA approval, which may enhance its market position in the treatment of ES-SCLC [1]